A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
Cheng Y, Wu C, Wu L, Zhao J, Zhao Y, Chen L, Xin Y, Zhang L, Pan P, Li X, Li J, Dong X, Tang K, Gao E, Yu F.
Cheng Y, et al. Among authors: zhang l.
Sci Rep. 2024 Feb 13;14(1):3598. doi: 10.1038/s41598-024-54223-5.
Sci Rep. 2024.
PMID: 38351146
Free PMC article.
Clinical Trial.